Post-PCI Antithrombotic Treatment With High Bleeding Risk.
作者信息
Kinlay Scott
机构信息
VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
出版信息
J Am Coll Cardiol. 2022 Sep 27;80(13):1238-1240. doi: 10.1016/j.jacc.2022.07.015.
Abstract
摘要
相似文献
1
Post-PCI Antithrombotic Treatment With High Bleeding Risk.高出血风险患者经皮冠状动脉介入治疗后的抗栓治疗
J Am Coll Cardiol. 2022 Sep 27;80(13):1238-1240. doi: 10.1016/j.jacc.2022.07.015.
2
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.抗栓治疗在房颤和急性冠脉综合征患者中治疗药物或经皮冠状动脉介入或接受择期经皮冠状动脉介入治疗:从 AUGUSTUS 试验的见解。
Circulation. 2019 Dec 3;140(23):1921-1932. doi: 10.1161/CIRCULATIONAHA.119.043308. Epub 2019 Sep 26.
3
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.急性冠状动脉综合征或经皮冠状动脉介入治疗后早期和晚期心房颤动患者抗栓治疗的风险/获益权衡：来自 AUGUSTUS 的见解。
Circulation. 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29.
4
Dual Versus Triple Antithrombotic Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: An Updated Meta-Analysis.急性冠状动脉综合征或经皮冠状动脉介入治疗后房颤患者的双联与三联抗栓治疗：一项更新的荟萃分析
Cardiovasc Revasc Med. 2020 Feb;21(2):239-241. doi: 10.1016/j.carrev.2019.08.015. Epub 2019 Aug 20.
5
Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.双联或三联抗栓治疗患者的出血和缺血结局：系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):226-236. doi: 10.1093/ehjcvp/pvz021.
6
The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗的心房颤动患者中三联抗栓治疗的作用。
Prog Cardiovasc Dis. 2021 Nov-Dec;69:11-17. doi: 10.1016/j.pcad.2021.11.010. Epub 2021 Dec 6.
7
A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.一项比较经皮冠状动脉介入治疗的心房颤动患者双联与三联抗栓治疗的随机试验的系统评价。
Catheter Cardiovasc Interv. 2020 Aug;96(2):E102-E109. doi: 10.1002/ccd.28535. Epub 2019 Nov 11.
8
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.药物洗脱冠状动脉支架置入患者的房颤患病率、治疗及 6 年随访结果。
JACC Cardiovasc Interv. 2017 Jun 12;10(11):1075-1085. doi: 10.1016/j.jcin.2017.02.028. Epub 2017 May 17.
9
Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.经皮冠状动脉介入治疗的非瓣膜性心房颤动患者的当代抗栓治疗：希腊抗血小板心房颤动（GRAPE-AF）注册研究的原理和设计。
Cardiovasc Drugs Ther. 2018 Apr;32(2):191-196. doi: 10.1007/s10557-018-6789-7.
10
Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.非瓣膜性心房颤动患者行经皮冠状动脉介入治疗后发生卒中和脑出血的风险：比较双联与三联抗栓治疗的随机对照试验的系统评价和荟萃分析。
J Stroke Cerebrovasc Dis. 2021 Apr;30(4):105654. doi: 10.1016/j.jstrokecerebrovasdis.2021.105654. Epub 2021 Feb 10.
引用本文的文献
1
Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy.双联抗血小板治疗联合抗凝治疗：三联治疗的当前观点
Arch Med Sci Atheroscler Dis. 2023 Feb 28;8:e13-e18. doi: 10.5114/amsad/161172. eCollection 2023.
2
Long-Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second-Generation Drug-Eluting Stents: The Veterans Affairs Extended DAPT Study.第二代药物洗脱支架冠状动脉介入治疗后双联抗血小板治疗的长期结局和持续时间：退伍军人事务部延长 DAPT 研究。
J Am Heart Assoc. 2023 Jan 17;12(2):e027055. doi: 10.1161/JAHA.122.027055. Epub 2023 Jan 16.
本文引用的文献
1
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.心梗高出血风险患者冠脉支架术后的简化抗血小板治疗。
J Am Coll Cardiol. 2022 Sep 27;80(13):1220-1237. doi: 10.1016/j.jacc.2022.07.016.
2
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis.经皮冠状动脉介入治疗（PCI）中使用药物洗脱支架后高出血风险患者的双联抗血小板治疗时间：系统评价和荟萃分析。
Am Heart J. 2022 Aug;250:1-10. doi: 10.1016/j.ahj.2022.04.004. Epub 2022 Apr 15.
3
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.急性冠状动脉综合征患者双联抗血小板治疗 1 至 2 个月后氯吡格雷单药治疗与 12 个月双联抗血小板治疗的比较：STOPDAPT-2 ACS 随机临床试验。
JAMA Cardiol. 2022 Apr 1;7(4):407-417. doi: 10.1001/jamacardio.2021.5244.
4
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.替格瑞洛单药治疗有 MI 病史高危患者 PCI 术后：TWILIGHT 预设亚组研究。
JACC Cardiovasc Interv. 2022 Feb 14;15(3):282-293. doi: 10.1016/j.jcin.2021.11.005. Epub 2022 Jan 12.
5
Race and Ethnicity Considerations in Patients With Coronary Artery Disease and Stroke: JACC Focus Seminar 3/9.种族和民族因素在冠心病和脑卒中患者中的考虑：美国心脏病学会焦点研讨会 3/9。
J Am Coll Cardiol. 2021 Dec 14;78(24):2483-2492. doi: 10.1016/j.jacc.2021.05.051.
6
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.高出血风险患者经皮冠状动脉介入治疗（PCI）后的双联抗血小板治疗。
N Engl J Med. 2021 Oct 28;385(18):1643-1655. doi: 10.1056/NEJMoa2108749. Epub 2021 Aug 28.
7
Premature Discontinuation of Dual Antiplatelet Therapy After Coronary Stenting in Veterans: Characteristics and Long-Term Outcomes.退伍军人冠状动脉支架置入术后双联抗血小板治疗过早停药：特征和长期结局。
J Am Heart Assoc. 2021 May 4;10(9):e018481. doi: 10.1161/JAHA.120.018481. Epub 2021 Apr 26.
8
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update.接受经皮冠状动脉介入治疗的口服抗凝治疗心房颤动患者的抗栓治疗：北美视角：2021年更新
Circulation. 2021 Feb 9;143(6):583-596. doi: 10.1161/CIRCULATIONAHA.120.050438. Epub 2021 Feb 8.
9
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.短期双联抗血小板治疗继以 P2Y12 抑制剂单药治疗与第二代药物洗脱支架经皮冠状动脉介入治疗后延长双联抗血小板治疗：随机临床试验的系统评价和荟萃分析。
Eur Heart J. 2021 Jan 21;42(4):308-319. doi: 10.1093/eurheartj/ehaa739.
10
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.经皮冠状动脉介入治疗 ST 段抬高型心肌梗死患者合并心房颤动时使用达比加群的双联抗栓治疗：随机 RE-DUAL PCI 试验的事后分析。
EuroIntervention. 2021 Aug 27;17(6):474-480. doi: 10.4244/EIJ-D-20-00799.
Zotero 插件